Skip to main content
MedPathMedPath Home
Clinical Trials/RPCEC00000322
RPCEC00000322
Recruiting
未知

Treatment of lung lesions with autologous stem cells in patients recovered from COVID-19 (COVID-19)

Institute of Hematology and Immunology Dr. Jose Manuel Ballester Santovenia”0 sites20 target enrollmentJuly 3, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsung lesionsCOVID-19Lung InjuryLung DiseasesRespiratory Tract DiseasesThoracic InjuriesCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusSevere Acute Respiratory Syndrome

Overview

Phase
未知
Intervention
Not specified
Conditions
ung lesions
Sponsor
Institute of Hematology and Immunology Dr. Jose Manuel Ballester Santovenia”
Enrollment
20
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 3, 2020
End Date
February 15, 2021
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Institute of Hematology and Immunology Dr. Jose Manuel Ballester Santovenia”

Eligibility Criteria

Inclusion Criteria

  • •1\. Patient who gives his informed consent.
  • •2\. Negative viral load by PCR.
  • •3\. Over 18 and under 75\.
  • •4\. Lung damage evidenced by the criteria of radiological severity in COVID 19 on CT.

Exclusion Criteria

  • •2\. Patients with contraindications to the use of IOR® LEUKOCIM.
  • •3\. Patients who have taken amiodarone in the last 3 months, which can cause pulmonary fibrosis.
  • •4\. Patients with malignant tumor in the last 5 years.
  • •5\. Patients with decompensated heart and kidney disease.
  • •6\. Patients with liver disease whose presence of enzyme values 2 times above the upper level of the range of normal values is demonstrated in the blood chemistry.
  • •7\. Patients who have ultrasound images that require further study for diagnosis.
  • •8\. Pregnant women
  • •9\. Patients with severe lung infection who need anti\-infective treatment.
  • •10\. Patients with proven viral infections or positive serology.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus InfectioAcute Respiratory Distress Syndrome of COVID-19.COVID-19U07.1
IRCT20200217046526N2Iranian academic center for education culture and research60
Completed
Phase 1
Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infectio
IRCT20200217046526N1Iranian academic center for education culture and research6
Completed
Not Applicable
Autologous Stem Cell Treatment for Chronic Lung Disease StudyCOPDInterstitial Lung Disease
NCT03044431Lung Institute207
Recruiting
Not Applicable
Autologous stem cell transplantation for the treatment of refractory Crohn*s disease: mechanisms of succes
NL-OMON39547Sint Antonius Ziekenhuis15
Active, not recruiting
Not Applicable
Bone marrow cell treatment as treatment of multiple sclerosisMultiple SclerosisMedDRA version: 16.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2012-000734-19-ESBanc de Sang i Teixits